Instrument overview

TEVATeva Pharmaceutical Industries Limited

StockNYSEIsraelHealth careEU retail: available

−2.0% today · +107.2% over a year

6/10 A 1–10 summary of how an instrument compares with similar ones (same sector and region) by published rules. It describes today's data; it is not a price forecast. More in the glossary → «Balanced» — higher than 61% of the instruments we score

Trend, Stability: among the best of its peers. No dividend.

Balanced 6/106/10Balanced
Weights for long-horizon accumulation: more quality and trend, no dividend requirement. These are three ways to weigh the same factors, not three properties of the instrument; Income compares within the sector, so a low yield can still score high. More in the glossary →6/10
Default weights: value, quality, trend, stability and dividend safety together. These are three ways to weigh the same factors, not three properties of the instrument; Income compares within the sector, so a low yield can still score high. More in the glossary →6/10
Weights for income: dividend safety counts most; shown for dividend payers only. These are three ways to weigh the same factors, not three properties of the instrument; Income compares within the sector, so a low yield can still score high. More in the glossary →—/10

The Smart Score (1–10) describes how this instrument compares with its peers on published, rules-based measures of value, quality, trend, stability and dividend safety. It is not a forecast and not personal advice.

Compared with: all companies in Asia-Pacific (n = 61)

Current rating first published: · last recomputed · rating log

Factor scores

How cheap the company is versus peers: earnings, cash flow, book value and sales relative to its price. More in the glossary →better than 56% of peers
Profitability, balance-sheet safety, growth and capital discipline versus peers. More in the glossary →better than 22% of peers
Price trend over the last 12 and 6 months (excluding the last month) and distance from the 52-week high. More in the glossary →better than 93% of peers
Lower price swings, lower market sensitivity (beta) and shallower drawdowns score higher. More in the glossary →better than 84% of peers

Percentiles within the peer group (100 = the best of its peers); dividend safety in points.

Main drivers

  • Gross profit growth / assets (5 y)weighs on the score · better than 18% of peers
  • 12-month trend (ex last month)supports the score · better than 83% of peers
  • Volatility (1 y)supports the score · better than 83% of peers

Red flags and notes

  • Caution. Net debt above 4× EBITDA or interest cover below 2×. More in the glossary → Net debt above 4× EBITDA or interest cover below 2×.

Price chart

Interactive chart by TradingView: exchange prices are delayed, crypto and currencies are live.

Key metrics

Valuation

P/E
65.0
P/B
5.9
P/S
2.7
EV/EBIT
36.8
Free-cash-flow yield
2.9%
Market cap (EUR)
€41B

Profitability and debt

Return on equity
9.7%
Return on invested capital
7.4%
Gross margin
52.5%
Net debt / EBITDA
5.01

Dividends

Dividend yield
0.00%
Payout ratio
0%
Years of dividend growth
0

Returns and risk

1 day
−2.0%
1 month
+1.0%
1 year
+107.2%
Volatility, 1 yr
37.9%
Max drawdown, 1 yr
−21.8%
Beta
0.81

Ratios from SEC filings and end-of-day prices; returns are price changes without dividends.

News and filings

No recent news or filings in our sources.

Score changes in the last 12 months

Every published rating and change, logged when it was published (EU Market Abuse Regulation).

Show the log: 1 entry
DateEventBalancedGrowth · IncomeWarningsPrice at publication
First rating 6/10 6 · — Available with Invest Pro

Ratings are rules-based descriptions, valid until the next scoring run (about 06:20 and 21:50 UTC) and the same for every visitor.